A Placebo-Controlled Trial of Folate With B12 in Patients With Schizophrenia With Residual Symptoms in Ethiopia
Latest Information Update: 18 Sep 2021
Price :
$35 *
At a glance
- Drugs Cyanocobalamin/folic-acid (Primary)
- Indications Schizophrenia
- Focus Therapeutic Use
- 15 Aug 2018 Biomarkers information updated
- 01 Jul 2013 Planned end date changed from 1 Dec 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.
- 01 Jul 2013 Planned initiation date changed from 1 Jan 2013 to 1 Aug 2013 as reported by ClinicalTrials.gov record.